Supplementary Figure 1

A



B

Patient Enrollment and CAR T cell Manufacturing	
Characteristic	**No.**
Enrolled	10
Withdrew due to disease progression	2
Missed apheresis	1
Manufacturing failure	1
Received CAR T cell therapy	**6**

C

Response*	# of patients
PD	4
SD	2
PR	0
CR	0

Supplementary Figure 1. Study Design, enrollment and clinical response. **(A)** Autologous lymphocytes were collected by large-volume leukopheresis on day -28. Lymphocytes were isolated by elutriation; expanded *in vitro* for 10 ± 2 days using bead-immobilized anti-CD3/anti-CD28 antibodies; and then electroporated with anti-mesothelin ss1 scFv CAR mRNA during the manufacturing phase. Patients received three times per week intravenous infusions of CARTmeso cells for three weeks during the treatment phase. Repeated safety visits were conducted during the follow-up phase. CT imaging was performed at baseline and after 2 and 4 months. PET/CT imaging was performed at baseline, 28 days and 2 months. Optional tumor lesion biopsies were collected at baseline and within 3-7 after the last planned dose of RNA CAR T cells. **(B)** Patient enrollment and CAR T cell manufacturing feasibility. **(C)** Shown is the best overall response to mRNA CARTmeso cell therapy as measured by RECIST v1.1.